title: [Assessment of sugammadex use efficiency and safety for neuromuscular block reversion].
abstract: Blockade of neuromuscular conductivity is a considered one of basic part of a patient protection in a concept of a balanced multicomponent anesthesia. The controlled neuromuscular paralysis in a combination of a sedation, an analgesia and a hyporeflection not only provides comfortable conditions to surgeons for carrying out surgeries, but also allows to manage a gas exchange, blood circulation and a metabolism in a patient. However in clinical practice there is such complication after application of muscular relaxant (not depolarizing) as a residual curarization. The residual curarization is interfaced to deterioration of the respiratory answer to a hypoxemia, swallowing dysfunction that significantly increased risk of aspiration and risk of postoperative pulmonary complications. Until recent time acetylcholinesterase inhibitors or prolonged ALV before spontaneous regression of the neuromuscular block were applied in clinical practice for the purpose of restoration of adequate neuromuscular conductivity and elimination of a residual curarization. However there are number of the circumstances limiting application of preparations of this group including it is related with rather high frequency of side effects and lack of efficiency at the deep neuromuscular block. Today in an arsenal of the anesthesiologist there was the latest chemical - sugammadex. Sugammadex realizes a new approach to restoration of the neuromuscular conductivity.
authors.forename: P A
authors.initials: PA
authors.lastname: Kirienko
authors.forename: A V
authors.initials: AV
authors.lastname: Babaiants
authors.forename: I A
authors.initials: IA
authors.lastname: Shmakov
authors.forename: E S
authors.initials: ES
authors.lastname: Gorobets
authors.forename: A A-N
authors.initials: AA
authors.lastname: Él'dzharkiev
authors.forename: B R
authors.initials: BR
authors.lastname: Gel'fand
mesh_terms: D060666:Airway Extubation; D000732:Androstanols / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D000762:Anesthesia Recovery Period; D000771:Anesthesia, Intravenous / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019148:Neuromuscular Blockade; D003473:Neuromuscular Nondepolarizing Agents / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D011446:Prospective Studies; D000077123:Rocuronium; D000077122:Sugammadex; D013514:Surgical Procedures, Operative / Q000379:methods*; D013997:Time Factors; D047408:gamma-Cyclodextrins / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000732:Androstanols; D003473:Neuromuscular Nondepolarizing Agents; D047408:gamma-Cyclodextrins; D000077122:Sugammadex; D000077123:Rocuronium